Focused On-demand Library for RNA-binding protein FXR1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P51114

UPID:

FXR1_HUMAN

Alternative names:

FMR1 autosomal homolog 1; hFXR1p

Alternative UPACC:

P51114; A8K9B8; Q7Z450; Q8N6R8

Background:

RNA-binding protein FXR1, also known as FMR1 autosomal homolog 1 or hFXR1p, plays a pivotal role in mRNA translation and stability. It is essential for neurogenesis, muscle development, and spermatogenesis, binding to AU-rich elements in the 3'-UTR of target mRNAs. FXR1 promotes the assembly of mRNAs into cytoplasmic ribonucleoprotein granules, facilitating the translation of specific transcripts, including MYC and CDKN1A mRNAs.

Therapeutic significance:

FXR1's involvement in congenital myopathies 9A and 9B, characterized by severe muscle weakness and developmental delays, underscores its therapeutic potential. Understanding the role of RNA-binding protein FXR1 could open doors to potential therapeutic strategies for these muscular disorders.